Physician profile
Samuel S Kuo
NPI 1861478422
$4,807.29
in general payments reported to CMS, 2019-2025
40 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2021: $494 · 2022: $1,288 · 2023: $889 · 2024: $1,110 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.42 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $949.46 | 2019-2025 | Erleada, Akeega, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $346.29 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Lilly USA, LLC | $338.90 | 2022-2025 | Verzenio, Jaypirca |
| Pfizer INC. | $334.98 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $325.92 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Sobi, INC | $307.79 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $268.57 | 2021-2025 | |
| Incyte Corporation | $222.04 | 2021-2025 | Jakafi, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $218.89 | 2021-2025 | Libtayo |
| Amgen INC. | $189.93 | 2019-2023 | Lumakras |
| Kite Pharma, INC. | $96.27 | 2021-2023 | |
| Abbvie INC. | $91.92 | 2022-2024 | |
| Celgene Corporation | $91.88 | 2022-2024 | Reblozyl |
| Exelixis INC. | $91.73 | 2021-2023 | Cabometyx |
| Mirati Therapeutics, INC. | $82.03 | 2023 | Krazati |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.